Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
DNLI Stock Chart & Stats
$20.17
$0.28(1.32%)
At close: 4:00 PM EST
$20.17
$0.28(1.32%)
Day’s Range― - ―
52-Week Range$10.57 - $23.77
Previous CloseN/A
Volume399.31K
Average Volume (3M)1.57M
Market Cap
$3.20B
Enterprise Value$3.04B
Total Cash (Recent Filing)$867.88M
Total Debt (Recent Filing)$42.29M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
May 12, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding158,591,490
10 Day Avg. Volume1,731,682
30 Day Avg. Volume1,568,160
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)2.86
Price to Sales (P/S)0.00
P/FCF Ratio-6.86
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.06K
Enterprise Value/Ebitda-5.71
Forecast
1Y Price Target
$33.10Price Target Upside64.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.73
Revenue Forecast (FY)$49.17M
Bulls Say, Bears Say
Bulls Say
Financial And Commercial ReadinessSubstantial cash reserves and established commercial launch preparations position the company to fund late‑stage development and support a potential market introduction upon approval.
Pipeline DiversificationMultiple development candidates beyond the lead therapy provide additional paths to clinical advances and commercial value, reducing reliance on a single program for long‑term upside.
Platform Delivery TechnologyProprietary transport platform enables systemic delivery across the blood–brain barrier into neurons and muscle fibers, supporting potential treatment of both central nervous system and peripheral disease manifestations.
Bears Say
Evidence LimitationsRegulatory submissions that depend on open‑label and single‑arm data may be viewed as less conclusive by regulators, increasing uncertainty around approval outcomes.
Near‑term Commercial ConstraintsInitially limited addressable markets for the first approved indications could constrain near‑term revenue growth until broader opportunities are achieved.
Safety ConcernsInfusion‑related reactions and preclinical hypersensitivity signals have led to enhanced safety monitoring and a clinical hold on a program, creating material safety and development risks.
Denali Therapeutics News
DNLI FAQ
What was Denali Therapeutics’s price range in the past 12 months?
Denali Therapeutics lowest stock price was $10.57 and its highest was $23.77 in the past 12 months.
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $3.20B.
When is Denali Therapeutics’s upcoming earnings report date?
Denali Therapeutics’s upcoming earnings report date is May 12, 2026 which is in 50 days.
How were Denali Therapeutics’s earnings last quarter?
Denali Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.737 by $0.007.
Is Denali Therapeutics overvalued?
According to Wall Street analysts Denali Therapeutics’s price is currently Undervalued.
Does Denali Therapeutics pay dividends?
Denali Therapeutics does not currently pay dividends.
What is Denali Therapeutics’s EPS estimate?
Denali Therapeutics’s EPS estimate is -0.66.
How many shares outstanding does Denali Therapeutics have?
Denali Therapeutics has 158,591,490 shares outstanding.
What happened to Denali Therapeutics’s price movement after its last earnings report?
Denali Therapeutics reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.737. Following the earnings report the stock price went down -1.12%.
Which hedge fund is a major shareholder of Denali Therapeutics?
Currently, no hedge funds are holding shares in DNLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Denali Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.10 (64.11% Upside)
$33.10 (64.11% Upside)
Blogger Sentiment
Bullish
DNLI Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 965.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $864.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.05%
12-Months-Change
Fundamentals
Return on Equity
-50.13%
Trailing 12-Months
Asset Growth
-16.69%
Trailing 12-Months
Company Description
Denali Therapeutics
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
DNLI Stock 12 Month Forecast
Average Price Target
$33.10
▲(64.11% Upside)
Technical Analysis
Agios Pharma
―
Celcuity
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Ownership Overview
6.65% Insiders
24.31% Mutual Funds
34.00% Other Institutional Investors
19.56% Public Companies and
Individual Investors